The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: A framework for evaluating new vaccines in newly industrializing countries

Pediatric Infectious Disease Journal

Volumn 17, Issue 9 SUPPL., 1998, Pages

  Lagos, Rosanna ^a,b   Levine, Orin S ^c   Avendaño, Alfredo ^d   Horwitz, Isidoro ^b   Levine, Myron M ^e  

^a Centro para Vacunas en Desarrollo Chile   (Chile)

^b Servicio de Salud Metropolitano Norte   (Chile)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d Ministerio de Salud de Chile   (Chile)

^e University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Chile; Conjugate vaccines; Haemophilus influenzae; Haemophilus influenzae type b

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ANTIBODY RESPONSE; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CHILE; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INCIDENCE; INDUSTRIALIZATION; INFANT; PRESCHOOL CHILD; PRIORITY JOURNAL; VACCINATION;

CHILD, PRESCHOOL; CHILE; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; RANDOMIZED CONTROLLED TRIALS; TETANUS TOXOID; VACCINATION; VACCINES, CONJUGATE;

EID: 0031684406     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199809001-00010     Document Type: Conference Paper

References (49)

1. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992;340: 592-4.
2. Jonsdottir KE, Steingrimsson O, Olafsson O. Immunisation of infants in Iceland against Haemophilus influenzae type b. Lancet 1992;340:252-3.
3. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6.
4. Booy R, Hodgson S, Carpenter L, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994; 344:362-6.
5. Wenger JD, Heath PT, Moxon R, Booy R. Epidemiological impact of conjugate vaccines against invasive disease caused by Haemophilus influenzae type b. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New generation vaccines. New York: Dekker, 1996:489.
6. Ferreccio C, Ortiz E, Astroza L, Rivera C, Clemens J, Levine MM. A population-based retrospective assessment of the disease burden resulting from invasive Haemophilus influenzae in infants and young children in Santiago, Chile. Pediatr Infect Dis J 1990;9:488-94.
7. Ferreccio C, Clemens JD, Avendaño A, et al. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine co-administered in the same syringe with DTP at two, four and six months of age. Pediatr Infect Dis J 1992;10: 764-71.
8. Avendaño A, Ferreccio C, Lagos R, et al. Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1993;12:638-43.
9. Clemens JD, Ferreccio C, Levine MM, et al. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. JAMA 1992;267: 673-8.
10. Levine OS, Lagos R, Losonsky GA, et al. No adverse impact on protection against pertussis from combined administration of Haemophilus influenzae type b conjugate and diphtheria-tetanus toxoid-pertussis vaccines in the same syringe. J Infect Dis 1996;174:1341-4.
11. Levine OS, Granoff D, Lagos R, Fritzell B, Levine MM. Factors associated with superior antibody responses to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. Vaccine 1997;15:325-8.
12. Levine OS, Ortiz E, Contreras R, et al. Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile. Am J Epidemiol 1993;137:1221-8.
13. Lagos R, Horwitz I, Toro J, et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 1996;15:216-22.
14. Gonzalez Valdepena H, Wald ER, Rose E, Ungkanont K, Casselbrant ML. Epiglottitis and Haemophilus influenzae immunization: the Pittsburgh experience: a five-year review. Pediatrics 1995;96:424-7.
15. Gilbert GL, Johnson PD, Clements DA. Clinical manifestations and outcome of Haemophilus influenzae type b disease. J Paediatr Child Health 1995;31:99-104.
16. Hugosson S, Silfverdal SA, Garpenholt O, et al. Invasive Haemophilus influenzae disease: epidemiology and clinical spectrum before large-scale H. influenzae type b vaccination. Scand J Infect Dis 1995;27:63-7.
17. Herrera P, Prenzel I, Vildosola C. Pleural empyemas in children due to Haemophilus influenzae. Bol Med Hosp Infant Mex 1979;36:665-77.
18. Herrera P, Prenzel I, Topelberg S. Infecciónes graves por Haemophilus influenzae (IGHI) en el niño: I. Aspectos générales y espectro clinico. Rev Med Chile 1983;111:808-14.
19. Herrera P, Prenzel I, Arribas I, Rolón R, Topelberg S. Hemophilus influenzae en meningitis bacteriana aguda. Rev Pediatr 1975;18:89-91.
20. Santosham M, Kallman CH, Neff JM, Moxon ER. Absence of increasing incidence of meningitis caused by Haemophilus influenzae type b. J Infect Dis 1979;140:1009-12.
21. Peltola H, Kayhty H, Virtanen M, Makela PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984;310: 1561-6.
22. Ward JI, Lum MK, Hall DB, Silimperi DR, Bender TR. Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial. J Infect Dis 1986;153:17-26.
23. Gilsdorf JR. Bacterial meningitis in southwestern Alaska. Am J Epidemiol 1977;106:388-91.
24. Losonsky GA, Santosham M, Sehgal VM, Zwahlen A, Moxon ER. Haemophilus influenzae disease in the White Mountain Apaches: molecular epidemiology of a high risk population. Pediatr Infect Dis 1984;3:539-47.
25. Coulehan JL, Michaels RH, Williams E, et al. Bacterial meningitis in Navajo Indians. Public Health Rep 1976;91: 464-8.
26. Fraser DW, Geil CC, Feldman RA. Bacterial meningitis in Bernalillo County, New Mexico: a comparison with three other American populations. Am J Epidemiol 1974;100:29-34.
27. Fraser DW, Darby CP, Koehler RE, Jacobs CF, Feldman RA. Risk factors in bacterial meningitis: Charleston County, South Carolina. J Infect Dis 1973;127:271-7.
28. Murphy TV, Osterholm MT, Pierson LM, et al. Prospective surveillance of Haemophilus influenzae type b disease in Dallas County, Texas, and in Minnesota. Pediatrics 1987;79: 173-80.
29. Dagan R. A two-year prospective, nationwide study to determine the epidemiology and impact of invasive childhood Haemophilus influenzae type b infection in Israel: the Israeli Pediatric Bacteremia and Meningitis Group. Clin Infect Dis 1992;15:720-5.
30. Halfon-Yaniv I, Dagan R. Epidemiology of invasive Haemophilus influenzae type b infections in Bedouins and Jews in southern Israel. Pediatr Infect Dis J 1990;9:321-6.
31. Gilbert GL. Epidemiology of Haemophilus influenzae type b disease in Australia and New Zealand. Vaccine 1991;9: S10-13.
32. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992;121:355-62.
33. Watemberg N, Dagan R, Arbelli Y, et al. Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. Pediatr Infect Dis J 1991;10:758-63.
34. Greenberg DP, Vadheim CM, Partridge S, Chang SJ, Chiu CY, Ward JI. Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine in young infants: The Kaiser-UCLA Vaccine Study Group. J Infect Dis 1994;170: 76-81.
35. Cochi SL, Broome CV, Hightower AW. Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment. JAMA 1985;253:521-9.
36. Hay JW, Daum RS. Cost-benefit analysis of Haemophilus influenzae type b prevention: conjugate vaccination at eighteen months of age. Pediatr Infect Dis J 1990;9:246-52.
37. Hay JW, Daum RS. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection. Pediatrics 1987;80:319-29.
38. Clements DA, Booy R, Dagan R, et al. Comparison of the epidemiology and cost of Haemophilus influenzae type b disease in five Western countries. Pediatr Infect Dis J 1993; 12:362-7.
39. Clemens J, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries: efficacy or effectiveness? JAMA 1996;275:390-7.
40. Clemens J, Sack D, Rao M, et al. The design and analysis of cholera vaccine trials: recent lessons from Bangladesh. Int J Epidemiol 1993;22:724-30.
41. Clemens JD, Naficy A, Rao MR. Long-term evaluation of vaccine protection: methodological issues for Phase III trials and Phase IV studies. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New generation vaccines. New York: Dekker, 1996:47-67.
42. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 1988;10:212-41.
43. Comstock GW. Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol Rev 1994;16:77-89.
44. Comstock GW. Vaccine evaluation by case-control or prospective studies. Am J Epidemiol 1990;131:205-7.
45. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991;164:982-6.
46. Bijlmer HA. World-wide epidemiology of Haemophilus influenzae meningitis: industrialized versus non-industrialized countries. Vaccine 1991;9:S5-9.
47. Ward J. Prevention of invasive Haemophilus influenzae type b disease: lessons from vaccine efficacy trials. Vaccine 1991; 9:817-24.
48. Lagos R, Valenzueal MT, Levine OS, et al. Economisation of vaccination against Haemophilus influenzae type b: a randomized trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 1998;351:1472-6.
49. Aylward B, Kane M, Batson A, Scott RM. A framework for the evaluation of vaccines for use in the expanded programme on immunization. Vaccine 1994;12:1155-9.